Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2025-03-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Xilintai Pharmaceutical Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board meeting approval, the amount and purpose of the idle funds, investment scope, risk analysis, and compliance with regulatory requirements. The document is a formal disclosure about the company's financing fund management activities, specifically the use of idle raised funds for cash management, which is a capital/financing update. It is not a full financial report, audit, or earnings release, nor is it a voting result or management change announcement. The document length is 4024 characters, which is relatively short and typical for an announcement. Therefore, the best fitting category is Capital/Financing Update (CAP).
2025-03-24 Chinese
第六届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at a supervisory board meeting regarding the use of idle funds and cash management. It includes details about the meeting date, participants, and decisions made, but does not contain financial statements or detailed financial analysis. It is a formal announcement of board decisions rather than a full management report or financial report. The document is relatively short (1115 characters) and serves as a public disclosure of board resolutions. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-03-24 Chinese
关于SAL0140药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (SAL0140) by the National Medical Products Administration. It details the drug's basic information, clinical trial acceptance, and potential future development. The document is short (1164 characters) and serves as an official announcement of regulatory acceptance rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-13 Chinese
关于部分募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the completion of certain fundraising investment projects and the permanent allocation of surplus raised funds to working capital. It details the use and status of funds raised through a non-public stock issuance approved by the China Securities Regulatory Commission, including specific project investment amounts, progress, and reasons for surplus funds. The document includes board and supervisory committee meeting resolutions, opinions from the sponsor institution, and mentions that the matter will be submitted to the shareholders' meeting for approval. The content focuses on fundraising project completion and capital allocation rather than financial results, earnings, or audit opinions. It is a formal announcement about capital use and project status, fitting the category of Capital/Financing Update (CAP). The document length is about 4,862 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2025-01-24 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a sponsoring securities company regarding the completion of certain fundraising investment projects by Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the use and surplus of funds raised in a 2020 private placement, including specific project investment amounts, progress, and plans to permanently supplement working capital with surplus funds. The document includes detailed financial figures, project status, regulatory references, and opinions from the board, supervisory committee, and sponsor institution. It is not a brief announcement but a substantive report on fundraising project completion and fund usage. This fits the category of Capital/Financing Update (CAP), as it provides an update on the use of raised capital and changes in fund allocation. The document length (4504 characters) is sufficient to be a report rather than a mere announcement. Therefore, the classification is CAP with high confidence.
2025-01-24 Chinese
第六届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Shenzhen Xinlitai Pharmaceutical Co., Ltd. It details the board's approval of a proposal related to the completion of certain fundraising investment projects and the permanent supplementation of surplus raised funds into working capital. The document mentions that the matter still requires shareholder approval at a general meeting, which will be notified later. The text includes procedural details about the board meeting, voting results, and references to related disclosures. The document is short (1120 characters) and serves as a formal announcement of a board decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a shareholder meeting material or voting result announcement. It is best classified as a Board/Management Information filing, as it relates to board resolutions and management decisions.
2025-01-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.